Search research articles
Contact Us
Filters
Showing results (231-240 of 241) with videos related to
Page
of 25
Sort By:
The Lancet Regional Health. Southeast Asia
|
February 18, 2026
Comprehensive tuberculosis screening and preventive treatment in schools and congregate settings of India (2017-2024): a prospective study
Kunchok Dorjee, Sonam Topgyal, Rajesh K Sood, et al.
The New England Journal of Medicine
|
March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Susan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2016
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
The New England Journal of Medicine
|
May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Contemporary Clinical Trials
|
January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 241) with videos related to
Sort By:
Page
of 25
The Lancet Regional Health. Southeast Asia
|
February 18, 2026
Comprehensive tuberculosis screening and preventive treatment in schools and congregate settings of India (2017-2024): a prospective study
Kunchok Dorjee, Sonam Topgyal, Rajesh K Sood, et al.
The New England Journal of Medicine
|
March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Susan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2016
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
The New England Journal of Medicine
|
May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Contemporary Clinical Trials
|
January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Page
of 25